IntelGenx Corp.

Oral controlled-release drug delivery technologies have the ability to improve the performance of a wide variety of existing pharmaceutical compounds. The therapeutic effect of a drug compound will typically vary according to its bloodstream concentration. When the concentration is too low, efficacy may be reduced and when it is too high, side effects may increase.	Our product pipeline is well diversified from an indication as well as stage of development point of view. Presently, we have partnership agreements in place for five of our products and are in discussions with potential partners for the balance of our pipeline.

Oral controlled-release drug delivery technologies have the ability to improve the performance of a wide variety of existing pharmaceutical compounds. The therapeutic effect of a drug compound will typically vary according to its bloodstream concentration. When the concentration is too low, efficacy may be reduced and when it is too high, side effects may increase.

Our product pipeline is well diversified from an indication as well as stage of development point of view. Presently, we have partnership agreements in place for five of our products and are in discussions with potential partners for the balance of our pipeline.

Stock Information

04/14/2008
Intelgenx Corp. Forms Strategic Alliance with Dava Pharmaceuticals to Develop Cardiovascular Product Addressing a U.S. Market of $1.0 Billion
04/07/2008
IntelGenx Corp. and Cary Pharmaceuticals Confirm Agreement to Develop a Novel Antidepressant
03/28/2008
IntelGenx Technologies Corp. announces closing of private placement
01/07/2008
IntelGenx Corp. Forms Strategic Agreement with Azur Pharma to Develop Prenatal Vitamin Supplements Addressing a U.S. Market of $250 million
11/21/2007
IntelGenx Technologies Corp. Reports Financial Results for the First Nine Months of 2007

News Archive »